Bryan Garnier - Canopy Growth Corporation (WEED) CANOPY GROWTH: Disappointing Q2 revenue numbers and another big loss | SELL | CAD11 VS. CAD12.5 (-25%)

Report

Bryan Garnier

Nikolaas Faes

CANOPY GROWTH: Disappointing Q2 revenue numbers and another big loss | SELL | CAD11 VS. CAD12.5 (-25%)

CANOPY GROWTH - SELL | CAD11 VS. CAD12.5 (-25%)
Disappointing Q2 revenue numbers and another big loss

Organic decline in revenues of 34%
Delay expected break-even
Focussed on building US presence

08/11/2021 4 EN

Underlying

Canopy Growth Corporation

Canopy Growth is a licensed producer of medical marijuana in Canada. The principal activities of Co. are the production and sale of marijuana out of its facility in Smiths Falls, Ontario as regulated by the "Marijuana for Medical Purposes Regulations".

See profile

CA1380351009 Toronto Stock Exchange Canada

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Nikolaas Faes

Other Reports on these Companies

Fundamental Research

Delivra Health Brands Inc. (TSXV: DHB / OTCQB: DHBUF) A Health & Wellness Company Endorsed by Major Retail/Pharmacy Chains – Initiating Coverage

Fundamental Research Corp has issued a report entitled “A Health & Wellness Company Endorsed by Major Retail/Pharmacy Chains – Initiating Coverage” and dated September 12, 2023. The full report is now at

EUR 93.30

September 14, 2023 September 14, 2023 1 EN

TheScreener

Due to a more favourable environment, CANOPY GROWTH slightly increases to Slightly Negative

CANOPY GROWTH (CA), a company active in the Pharmaceuticals industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date March 18, 2022, the closing price was CAD 8.97 and its target price was estimated at CAD 6.40.

Free Trial

March 19, 2022 March 19, 2022 1 EN

Carbios and Hündgen sign a MoU for feedstock supply

This morning, Carbios announced the signing of a non-binding Memorandum of Understanding with Hündgen, a waste management expect in logistics, sorting and recycling services. The MoU concerns the supply of 15kt/year of post-consumer PET waste to be recycled in the company's first commercial plant f

14h / 28m 14h / 28m 1 EN

Paul Charpentier

Paul Charpentier

Worldline - not as weak as expected, but too early to jump in

Worldline reported 2.5% organic growth in Q1 2024, weak in absolute terms but better than anticipated by the market and us. We wait for a clear uptick in momentum and the confirmation of an improved profitability to turn positive on the stock; which is arguably far from expensive at 5.1x EV/NTM EBI

14h / 46m 14h / 46m 1 EN

Cedric Rossi

Cedric Rossi

adidas: The best sunny terrace in sporting goods currently...

During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We

15h / 4m 15h / 4m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CANOPY GROWTH: Disappointing Q2 revenue numbers and another big loss | SELL | CAD11 VS. CAD12.5 (-25%)

Delivra Health Brands Inc. (TSXV: DHB / OTCQB: DHBUF) A Health & Wellness Company Endorsed by Major Retail/Pharmacy Chains – Initiating Coverage

Due to a more favourable environment, CANOPY GROWTH slightly increases to Slightly Negative

Carbios and Hündgen sign a MoU for feedstock supply

Worldline - not as weak as expected, but too early to jump in

adidas: The best sunny terrace in sporting goods currently...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe